Drug Costs

"Drug Costs" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The amount that a health care institution or organization pays for its drugs. It is one component of the final price that is charged to the consumer (FEES, PHARMACEUTICAL or PRESCRIPTION FEES).

Descriptor ID	D016527
MeSH Number(s)	N03.219.151.400.350 N05.300.375.300
Concept/Terms	Drug Costs Drug Costs Cost, Drug Costs, Drug Drug Cost

Below are MeSH descriptors whose meaning is more general than "Drug Costs".

Health Care [N]
Health Care Economics and Organizations [N03]
Economics [N03.219]
Costs and Cost Analysis [N03.219.151]
Health Care Costs [N03.219.151.400]
Drug Costs [N03.219.151.400.350]
Health Care Quality, Access, and Evaluation [N05]
Delivery of Health Care [N05.300]
Health Care Costs [N05.300.375]
Drug Costs [N05.300.375.300]

Below are MeSH descriptors whose meaning is related to "Drug Costs".

Below are MeSH descriptors whose meaning is more specific than "Drug Costs".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Drug Costs" by people in this website by year, and whether "Drug Costs" was a major or minor topic of these publications.

Bar chart showing 60 publications over 25 distinct years, with a maximum of 6 publications in 1999 and 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1993	0	2	2
1994	0	2	2
1995	1	1	2
1999	2	4	6
2000	0	3	3
2001	1	1	2
2002	1	2	3
2003	0	1	1
2005	0	1	1
2007	0	2	2
2008	0	2	2
2009	0	2	2
2010	1	0	1
2011	1	1	2
2012	1	2	3
2013	1	0	1
2014	1	2	3
2015	1	1	2
2016	2	0	2
2017	2	2	4
2018	1	2	3
2019	2	4	6
2020	2	1	3
2021	0	1	1
2022	1	0	1

Below are the most recent publications written about "Drug Costs" by people in Profiles.

Watkins S, Toliver JC, Kim N, Whitmire S, Garvey WT. Economic outcomes of antiobesity medication use among adults in the United States: A retrospective cohort study. J Manag Care Spec Pharm. 2022 Oct; 28(10):1066-1079.

View in: PubMed
Corwin TR, Ozieh MN, Garacci E, Palatnik A, Egede LE. The relationship between financial hardship and incident diabetic kidney disease in older US adults - a longitudinal study. BMC Nephrol. 2021 05 05; 22(1):167.

View in: PubMed
Barber MRW, Hanly JG, Su L, Urowitz MB, St Pierre Y, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin PR, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Farewell V, Stoll T, Buyon J, Clarke AE. Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care Res (Hoboken). 2020 12; 72(12):1800-1808.

View in: PubMed
Mattingly TJ, Love BL. Changes in Cost-Effectiveness for Chronic Hepatitis C Virus Pharmacotherapy: The Case for Continuous Cost-Effectiveness Analyses. J Manag Care Spec Pharm. 2020 Jul; 26(7):879-886.

View in: PubMed
Elmunzer BJ, Hernandez I, Gellad WF. The Skyrocketing Cost of Rectal Indomethacin. JAMA Intern Med. 2020 05 01; 180(5):631-632.

View in: PubMed
Lekoubou A, Bishu KG, Ovbiagele B. Costs and cost-drivers of a diagnosis of depression among adults with epilepsy in the United States. Epilepsy Behav. 2019 09; 98(Pt A):96-100.

View in: PubMed
Low D, Simpson KN, Rissmiller R, James E. A new side of sarcoidosis: medication and hospitalization use in a privately insured patient population. Sarcoidosis Vasc Diffuse Lung Dis. 2019; 36(2):124-129.

View in: PubMed
Chen B, Nagai S, Armitage JO, Witherspoon B, Nabhan C, Godwin AC, Yang YT, Kommalapati A, Tella SH, DeAngelis C, Raisch DW, Sartor O, Hrushesky WJ, Ray PS, Yarnold PR, Love BL, Norris LB, Knopf K, Bobolts L, Riente J, Luminari S, Kane RC, Hoque S, Bennett CL. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019 04; 24(4):537-548.

View in: PubMed
Qureshi ZP, Nagai S, Bennett CL. Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done? JAMA Oncol. 2019 03 01; 5(3):297-298.

View in: PubMed
Picone MF, Wisniewski CS, Hayes GL. Use of economic predictions to make formulary decisions. Am J Health Syst Pharm. 2019 Feb 08; 76(Supplement_1):S15-S20.

View in: PubMed

People

Explore

Similar Concepts

Top Journals